NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).

Sponsor

Tmunity Therapeutics

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04025216

Official Title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

First Posted : July 18, 2019

Click here to see details on ClinicalTrials.gov

---

Biological: CART-TnMUC1

Drug: Cyclophosphamide

Drug: Fludarabine

---

Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes

Autologous Tn-MUC1-specific CAR T-lymphocytes (Code C165433)

Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes

Autologous Anti-TnMUC1-CAR-expressing T-lymphocytes

Autologous CART-TnMUC1 Cells

Autologous Tn-MUC1-specific CAR T Cells

Autologous Tn-MUC1-specific CAR T-lymphocytes

Autologous TnMUC1-targeted Genetically-Modified CAR T Cells

---

Locations

United States, Arizona

United States, California

United States, Florida

United States, Illinois

United States, Missouri

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington